Abstract: A new cell line and an antibody for determining the activity of botulinum toxin are disclosed. Also disclosed is a method of determining the activity of botulinum toxin using the cell line and/or the antibody.
Abstract: A new cell line and an antibody for determining the activity of botulinum toxin are disclosed. Also disclosed is a method of determining the activity of botulinum toxin using the cell line and/or the antibody.
Abstract: A new cell line and an antibody for determining the activity of botulinum toxin are disclosed. Also disclosed is a method of determining the activity of botulinum toxin using the cell line and/or the antibody.
Abstract: Anew cell line and an antibody for determining the activity of botulinum toxin are disclosed. Also disclosed is a method of determining the activity of botulinum toxin using the cell line and/or the antibody.
Abstract: The present invention relates to a cell and an antibody for determining the activity of botulinum toxin, and a method of determining the activity of botulinum toxin using the same.
Abstract: The present invention relates to microstructure formulation techniques for botulinum toxin. The microstructure formulation techniques for botulinum toxin according to the present invention make it possible to precisely control the concentration of botulinum toxin and to alleviate the pain occurring when botulinum toxin is administered into the human body, and also enable botulinum toxin to be accurately administered to a desired position. Thus, the present invention is expected to greatly contribute to the safe and convenient medical use of botulinum toxin.
Type:
Grant
Filed:
October 12, 2017
Date of Patent:
January 7, 2020
Assignees:
Hugel, Inc., Small Lab Co., Ltd.
Inventors:
Kyeong Yeop Moon, Chang Jin Lee, Dae Gun Kim, Dong Hoon Oh, Do Hyun Kang, Woo Ran Lee, Jeong Gyu Lee, Jun Jin Yoon